Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: 2 | Vintage Vibes

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Viking Therapeutics: The High-Stakes Weight Loss Contender

Viking Therapeutics is positioning itself as a contender in the obesity market with a dual strategy of rapid clinical progress and commercial preparation.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Barchart

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

Eli Lilly Stock Outlook: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

Barchart

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

MarketBeat

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

Barchart

This NVIDIA Partnership Shows How Big AI Can Really Get

NVIDIA is well-positioned to dominate AI markets across industries and verticals for years to come; analysts point to a 40% upside.

MarketBeat

MarketBeat Week in Review – 12/29 - 01/02

Stocks staged a rally on the first day of trading in 2026, which aligns with the general sense that the markets will grind higher, despite valuation concerns

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.

MarketBeat

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

Benzinga

Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFs

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly…

Barchart

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

A Conductor For The Orchestra: Seasoned Healthcare Executive Raises $52 Million For An AI Health Startup

Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide…

Barchart

Eli Lilly’s Stock Price Has Fattened Up Like a Thanksgiving Turkey. Time to (Options) Collar That Green!

As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Benzinga

AI Just Sparked Biotech's Biggest Rally Since 2004 — Why Isn't Anyone Talking About It?

While everyone's watching AI reshape chipmakers and tech sectors, the most profound transformation may be unfolding where no one’s looking: biotech.

Barchart

How Is Eli Lilly’s Stock Performance Compared to Other Pharmaceuticals?

Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Benzinga

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo Nordisk’s (NYSE:NVO) nearly 11% pre-market drop on Monday and subsequent 9% dip at market open, in the aftermath of disappointing topline results from its evoke/evoke+ Alzheimer’s trials, is more than a pipeline setback. It’s a stress test for healthcare ETFs that have quietly become GLP-1 momentum vehicles. With two…

Barchart

Eli Lilly Stock Just Joined the $1 Trillion Club. Should You Buy LLY Here?

Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will push meaningfully higher in 2026.

Barchart

Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain highly confident,...

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.